 Lille France, Cambridge Massachusetts, United States, December 7, 2020 GENFIT Nasdaq and Euronext: GNFT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announces that it has signed bond repurchase agreements with holders of its convertible bonds maturing in October 2022 the OCEANEs. 